<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)
of the<BR STYLE="mso-special-character: line-break">
<BR STYLE="mso-special-character: line-break">
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): July 13, 2012</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MUSCLEPHARM CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Charter)</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">000-53166</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">77-0664193</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">(State or Other Jurisdiction<BR> of Incorporation)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(Commission File Number)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4721 Ironton Street, Building A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Denver, Colorado 80239</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of Principal Executive Offices)<BR>
<BR>
<B>(303) 396-6100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s Telephone Number, Including
Area Code)<BR>
<BR>
<B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<I>see </I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="width: 2%; font-family: Wingdings">o</TD>
    <TD STYLE="width: 93%">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="font-family: Wingdings">o</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="font-family: Wingdings">o</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&nbsp;</TD>
    <TD STYLE="font-family: Wingdings">o</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 1.01. Entry into a Material Definitive
Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Securities Purchase Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">On
July 13, 2012, the Company entered into a Securities Purchase Agreement (the &quot;SPA&quot;) with six investors pursuant to which
the Company (i) sold</FONT> 100,000,000 shares of its common stock, $0.001 par value per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;),
at a per share price of $0.01 for an aggregate purchase price of up to $1,000,000 and (ii) issued warrants with a term of five
years (the &ldquo;<B><I>Warrants</I></B>&rdquo;) to purchase an aggregate of up to 50,000,000 shares of Common Stock at an exercise
price per share of $0.01, subject anti-dilution provisions reducing the exercise price if the Company issues shares for less than
the exercise price of the Warrants<FONT STYLE="color: black">. The SPA includes price protection provisions whereby f</FONT>or
so long as an Investor holds shares of the Common Stock purchased pursuant to the SPA, in the event that the Company issues or
sells any shares of Common Stock or any Common Stock equivalent pursuant to which shares of Common Stock may be acquired or issued
at a price less than the $0.01 per share purchase price (the &quot;Diluted Price Per Share&quot;), then the Company is obligated
to issue additional shares of Common Stock to each such Investor, for no additional consideration, so that the Investor's cost
basis in the shares originally purchased plus the shares issued due to the price protection provision equals the Diluted Price
Per Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of the SPA, the Company may sell an additional 100,000,000 shares of Common Stock and 50,000,000 Warrants in one or more additional
closings pursuant to the terms of the SPA; provided, however, that each subsequent closing is for a minimum of $250,000 and the
holders of a majority of the Common Stock/Warrants purchased in the initial closing described above have consented to the sale
of the additional securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to a Registration
Rights Agreement, the Company is obligated to register for resale with the Securities and Exchange Commission the shares of Common
Stock received by the investors in the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Consulting Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 14, 2012, t<FONT STYLE="color: black">he
Company entered into two consulting agreements (the &ldquo;Consulting Agreement&rdquo;) with two corporate advisers to provide
certain consulting services relating to introducing the Company to banking relationships and advising on corporate structure issues
and strategic acquisition planning (the &ldquo;Services&rdquo;). Each agreement has a term of 12 months.&nbsp;&nbsp;In consideration
for the Services, the Company agreed to issue as consideration</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
for the Services shares of the Company&rsquo;s common stock (the &ldquo;<U>Compensation Shares</U>&rdquo;) in an amount equal to
4.2% of the outstanding shares of common stock of the Company on a fully diluted (as-converted) basis upon the Company effectuating
a contemplated reverse stock split and completion of a qualified financing, which requirement has been met by the completion of
the private placement described above. Notwithstanding the foregoing, in the event that the Company fails to consummate the reverse
stock split within 45 days from the date of the agreement, the Company is required to take all requisite action to increase the
number of its authorized common stock outstanding and issue the Compensation Shares no later than 60 days from the date of the
agreement. In addition, until the Company has issued and outstanding 3.5 billion shares of Common Stock (subject to adjustment
for stock splits), the Company is obligated to ensure that the Consultant maintains its 4.2% fully diluted equity position by issuing
additional shares for no further consideration on a fully diluted basis after future issuances of common stock or securities exercisable
for or convertible into common stock (an &quot;Equity Anti-Dilution Adjustment&quot;).</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company fails
to issue the Compensation Shares within 60 days of the date of the agreement, and such failure remains uncured for 15 days, then
the Equity Anti-Dilution Adjustment rights will be extended to a period of two years from the date of the agreement. In addition,
the Company shall not affect any change of control transaction unless the Consultant shall have received all of the Compensation
Shares it is entitled to receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has agreed
to register with the Securities and Exchange Commission the Compensation Shares for resale by the Consultants.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Consultant is
an&nbsp;&nbsp;&ldquo;accredited investor,&rdquo; as such term is defined in the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;) and will be issued in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506)
under the Securities Act of 1933 and corresponding provisions of state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02. Unregistered Sales of Equity Securities. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">As
noted in Item 1.01 above, on July 13, 2012, the Company (i) sold</FONT> 100,000,000 shares of its common stock, $0.001 par value
per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), at a per share price of $0.01 for an aggregate purchase price of up to
$1,000,000 and (ii) issued warrants with a term of five years (the &ldquo;<B><I>Warrants</I></B>&rdquo;) to purchase an aggregate
of up to 50,000,000 shares of Common Stock at an exercise price per share of $0.01, subject anti-dilution provisions reducing the
exercise price if the Company issues shares for less than the exercise price of the Warrants<FONT STYLE="color: black">. The Common
Stock and Warrants were sold and issued in a private placement to six &quot;accredited investors,&quot; as such term is defined
in the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) and were issued in reliance on the exemption from
registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933 and corresponding provisions
of state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black">On
July 14, 2012, the Company appointed Mark Groussman to its Board of Directors. Mr. Groussman's appointment to the Board was pursuant
to the terms of one of the Consulting Agreements reported in Item 1.01 above between the Company and </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Melechdavid,
Inc. (the &quot;Consultant&quot;), a corporation owned by Mr. Groussman</FONT><FONT STYLE="color: black">. Additional terms of
the Consulting Agreement are described under Item 1.01 above.</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biographical Background:
Mark Groussman, age 39, was appointed as the Chief Executive Officer of American Strategic Minerals Corporation in June 2012. Mr.
Groussman has been a consultant and investor in both private and public companies for the past 11 years. Mr. Groussman has been
the managing member of Bull Hunter LLC since 2001 and the president of Melechdavid, Inc. since 2001. Both of these companies invest
in small capitalization in private and public companies. Mr. Groussman received his B.A. from George Washington University in 1995
and received a M.S. in Real Estate Finance from New York University in 1999.Mr. Groussman's appointment to the Board was pursuant
to the terms of a consulting agreement between the Company and Melechdavid, Inc., a corporation owned by Mr. Groussman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01.&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Exhibits listed below are furnished
as Exhibits to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; padding: 0; text-decoration: underline; text-align: justify; text-indent: 0; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">Exhibit No.</TD>
    <TD STYLE="width: 87%; padding: 0; text-decoration: underline; text-align: justify; text-indent: 0; border: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">10.1</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border: Black 1pt solid">Securities Purchase Agreement dated July 10, 2012 by and between MusclePharm Corporation and Subscribers set forth therein.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">10.2</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border: Black 1pt solid">Consulting Agreement between MusclePharm Corporation and Melechdavid, Inc. dated July 12, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">10.3</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; border: Black 1pt solid">Consulting Agreement between MusclePharm Corporation and GRQ Consultants, Inc. dated July 12, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&#9;Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-weight: bold">MUSCLEPHARM CORPORATION</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Dated: July 19, 2012&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">By:</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">/s/ Brad J. Pyatt</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Brad J. Pyatt, Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v319010_8k.htm", "description": "8-K CURRENT REPORT", "secsgml_size_bytes": 25144}]
{"company-data": {"conformed-name": "MusclePharm Corp", "cik": "0001415684", "assigned-sic": "2834", "irs-number": "770664193", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53166", "film-number": "12970068"}, "business-address": {"street1": "4721 IRONTON STREET", "city": "DENVER", "state": "CO", "zip": "80239", "phone": "(800) 210-7369"}, "mail-address": {"street1": "4721 IRONTON STREET", "city": "DENVER", "state": "CO", "zip": "80239"}, "former-company": {"former-conformed-name": "Tone in Twenty", "date-changed": "20071018"}}
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): July 13, 2012
MUSCLEPHARM CORPORATION
(Exact Name of Registrant as Specified in
Charter)
Nevada
000-53166
77-0664193
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4721 Ironton Street, Building A
Denver, Colorado 80239
(Address of Principal Executive Offices)
(303) 396-6100
(Registrant's Telephone Number, Including
Area Code)
N/A
(Former Name or Former Address if Changed
Since Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
Item 1.01. Entry into a Material Definitive
Agreement.
Securities Purchase Agreement
On
July 13, 2012, the Company entered into a Securities Purchase Agreement (the "SPA") with six investors pursuant to which
the Company (i) sold
100,000,000 shares of its common stock, $0.001 par value per share (the "
Common Stock
"),
at a per share price of $0.01 for an aggregate purchase price of up to $1,000,000 and (ii) issued warrants with a term of five
years (the "
Warrants
") to purchase an aggregate of up to 50,000,000 shares of Common Stock at an exercise
price per share of $0.01, subject anti-dilution provisions reducing the exercise price if the Company issues shares for less than
the exercise price of the Warrants
. The SPA includes price protection provisions whereby f
or
so long as an Investor holds shares of the Common Stock purchased pursuant to the SPA, in the event that the Company issues or
sells any shares of Common Stock or any Common Stock equivalent pursuant to which shares of Common Stock may be acquired or issued
at a price less than the $0.01 per share purchase price (the "Diluted Price Per Share"), then the Company is obligated
to issue additional shares of Common Stock to each such Investor, for no additional consideration, so that the Investor's cost
basis in the shares originally purchased plus the shares issued due to the price protection provision equals the Diluted Price
Per Share.
Pursuant to the terms
of the SPA, the Company may sell an additional 100,000,000 shares of Common Stock and 50,000,000 Warrants in one or more additional
closings pursuant to the terms of the SPA; provided, however, that each subsequent closing is for a minimum of $250,000 and the
holders of a majority of the Common Stock/Warrants purchased in the initial closing described above have consented to the sale
of the additional securities.
Pursuant to a Registration
Rights Agreement, the Company is obligated to register for resale with the Securities and Exchange Commission the shares of Common
Stock received by the investors in the private placement.
Consulting Agreements
On July 14, 2012, t
he
Company entered into two consulting agreements (the "Consulting Agreement") with two corporate advisers to provide
certain consulting services relating to introducing the Company to banking relationships and advising on corporate structure issues
and strategic acquisition planning (the "Services"). Each agreement has a term of 12 months.  In consideration
for the Services, the Company agreed to issue as consideration
for the Services shares of the Company's common stock (the "
Compensation Shares
") in an amount equal to
4.2% of the outstanding shares of common stock of the Company on a fully diluted (as-converted) basis upon the Company effectuating
a contemplated reverse stock split and completion of a qualified financing, which requirement has been met by the completion of
the private placement described above. Notwithstanding the foregoing, in the event that the Company fails to consummate the reverse
stock split within 45 days from the date of the agreement, the Company is required to take all requisite action to increase the
number of its authorized common stock outstanding and issue the Compensation Shares no later than 60 days from the date of the
agreement. In addition, until the Company has issued and outstanding 3.5 billion shares of Common Stock (subject to adjustment
for stock splits), the Company is obligated to ensure that the Consultant maintains its 4.2% fully diluted equity position by issuing
additional shares for no further consideration on a fully diluted basis after future issuances of common stock or securities exercisable
for or convertible into common stock (an "Equity Anti-Dilution Adjustment").
2
If the Company fails
to issue the Compensation Shares within 60 days of the date of the agreement, and such failure remains uncured for 15 days, then
the Equity Anti-Dilution Adjustment rights will be extended to a period of two years from the date of the agreement. In addition,
the Company shall not affect any change of control transaction unless the Consultant shall have received all of the Compensation
Shares it is entitled to receive.
The Company has agreed
to register with the Securities and Exchange Commission the Compensation Shares for resale by the Consultants.
Each Consultant is
an  "accredited investor," as such term is defined in the Securities Act of 1933, as amended (the "Securities
Act") and will be issued in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506)
under the Securities Act of 1933 and corresponding provisions of state securities laws.
Item 3.02. Unregistered Sales of Equity Securities.
As
noted in Item 1.01 above, on July 13, 2012, the Company (i) sold
100,000,000 shares of its common stock, $0.001 par value
per share (the "
Common Stock
"), at a per share price of $0.01 for an aggregate purchase price of up to
$1,000,000 and (ii) issued warrants with a term of five years (the "
Warrants
") to purchase an aggregate
of up to 50,000,000 shares of Common Stock at an exercise price per share of $0.01, subject anti-dilution provisions reducing the
exercise price if the Company issues shares for less than the exercise price of the Warrants
. The Common
Stock and Warrants were sold and issued in a private placement to six "accredited investors," as such term is defined
in the Securities Act of 1933, as amended (the "Securities Act") and were issued in reliance on the exemption from
registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act of 1933 and corresponding provisions
of state securities laws.
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
July 14, 2012, the Company appointed Mark Groussman to its Board of Directors. Mr. Groussman's appointment to the Board was pursuant
to the terms of one of the Consulting Agreements reported in Item 1.01 above between the Company and
Melechdavid,
Inc. (the "Consultant"), a corporation owned by Mr. Groussman
. Additional terms of
the Consulting Agreement are described under Item 1.01 above.
3
Biographical Background:
Mark Groussman, age 39, was appointed as the Chief Executive Officer of American Strategic Minerals Corporation in June 2012. Mr.
Groussman has been a consultant and investor in both private and public companies for the past 11 years. Mr. Groussman has been
the managing member of Bull Hunter LLC since 2001 and the president of Melechdavid, Inc. since 2001. Both of these companies invest
in small capitalization in private and public companies. Mr. Groussman received his B.A. from George Washington University in 1995
and received a M.S. in Real Estate Finance from New York University in 1999.Mr. Groussman's appointment to the Board was pursuant
to the terms of a consulting agreement between the Company and Melechdavid, Inc., a corporation owned by Mr. Groussman.
Item 9.01.  Financial Statements and Exhibits.
(d)         Exhibits
The Exhibits listed below are furnished
as Exhibits to this Current Report on Form 8-K.
Exhibit No.
Description
10.1
Securities Purchase Agreement dated July 10, 2012 by and between MusclePharm Corporation and Subscribers set forth therein.
10.2
Consulting Agreement between MusclePharm Corporation and Melechdavid, Inc. dated July 12, 2012.
10.3
Consulting Agreement between MusclePharm Corporation and GRQ Consultants, Inc. dated July 12, 2012.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
MUSCLEPHARM CORPORATION
Dated: July 19, 2012
By:
/s/ Brad J. Pyatt
Brad J. Pyatt, Chief Executive Officer
4